See more : Hwaseung Enterprise Co., Ltd. (241590.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Allogene Therapeutics, Inc. (ALLO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allogene Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- SRF Limited (SRF.BO) Income Statement Analysis – Financial Results
- Huntsman Exploration Inc. (HMAN.V) Income Statement Analysis – Financial Results
- Mr Max Holdings Ltd. (8203.T) Income Statement Analysis – Financial Results
- Kingsoft Corporation Limited (3888.HK) Income Statement Analysis – Financial Results
- Microchip Technology Inc (MCP.DE) Income Statement Analysis – Financial Results
Allogene Therapeutics, Inc. (ALLO)
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 95.00K | 243.00K | 38.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 242.91M | 16.73M | 13.07M | 11.54M | 5.03M | 1.50M | 0.00 |
| Gross Profit | -242.82M | -16.49M | 25.42M | -11.54M | -5.03M | -1.50M | 0.00 |
| Gross Profit Ratio | -255,598.95% | -6,783.95% | 66.06% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 242.91M | 256.39M | 220.18M | 192.99M | 144.54M | 151.86M | 0.00 |
| General & Administrative | 71.67M | 79.31M | 74.11M | 65.26M | 57.47M | 40.98M | 24.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -22.00K |
| SG&A | 71.67M | 79.31M | 74.11M | 65.26M | 57.47M | 40.98M | 2.00K |
| Other Expenses | 13.25M | -1.75M | -2.93M | -1.14M | -268.00K | -21.21M | 0.00 |
| Operating Expenses | 327.83M | 335.69M | 294.28M | 258.24M | 202.01M | 192.84M | 2.00K |
| Cost & Expenses | 327.83M | 335.69M | 294.28M | 258.24M | 202.01M | 192.84M | 2.00K |
| Interest Income | 18.31M | 4.57M | 1.71M | 9.16M | 17.35M | 5.79M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.36M | 0.00 |
| Depreciation & Amortization | 14.20M | 14.30M | 10.45M | 11.54M | 5.03M | 1.50M | 24.00K |
| EBITDA | -300.29M | -321.24M | -169.74M | -250.81M | -179.90M | -206.76M | 22.00K |
| EBITDA Ratio | -316,097.89% | -138,044.86% | -664.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -327.74M | -335.45M | -255.79M | -258.24M | -202.01M | -192.84M | -2.00K |
| Operating Income Ratio | -344,986.32% | -138,044.86% | -664.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 472.00K | -4.88M | -1.86M | 8.02M | 17.08M | -18.78M | -22.00K |
| Income Before Tax | -327.27M | -332.63M | -257.01M | -250.22M | -184.93M | -211.62M | -2.00K |
| Income Before Tax Ratio | -344,489.47% | -136,885.60% | -667.74% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.82M | -12.17M | -16.75M | -331.00K | -117.00K | -24.00K |
| Net Income | -327.27M | -329.82M | -244.84M | -233.47M | -184.59M | -211.51M | -2.00K |
| Net Income Ratio | -344,489.47% | -135,726.34% | -636.12% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.09 | -2.30 | -1.80 | -1.94 | -1.83 | -7.31 | 0.00 |
| EPS Diluted | -2.09 | -2.30 | -1.80 | -1.94 | -1.83 | -7.31 | 0.00 |
| Weighted Avg Shares Out | 156.93M | 143.15M | 135.82M | 120.37M | 101.06M | 28.95M | 117.93M |
| Weighted Avg Shares Out (Dil) | 156.93M | 143.15M | 135.82M | 120.37M | 101.06M | 28.95M | 117.93M |
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation - Allogene Therapeutics (NASDAQ:ALLO), ARK Innovation ETF (ARCA:ARKK)
3 Meme Stocks to Sell and Replace With Meme Coins
Allogene Therapeutics Announces Q2 Investor Conference Participation
How Allogene (ALLO) Stock Stands Out in a Strong Industry
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Source: https://incomestatements.info
Category: Stock Reports